Skip Navigation
Skip to contents

J Korean Acad Nurs : Journal of Korean Academy of Nursing

OPEN ACCESS

Articles

Page Path
HOME > J Korean Acad Nurs > Volume 44(6); 2014 > Article
Original Article
Reliability and Validity of the Korean Version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire to Assess Chemotherapy-induced Peripheral Neuropathy
Hye Young Kim1, Jeong Hee Kang1, Hyun Jo Youn2, Hyang Sook So3, Chi Eun Song4, Seo Young Chae5, Sung Hoo Jung2, Sung Reul Kim1, Ji Young Kim1
Journal of Korean Academy of Nursing 2014;44(6):735-742.
DOI: https://doi.org/10.4040/jkan.2014.44.6.735
Published online: December 15, 2014

1College of Nursing, Chonbuk National University, Jeonju

2Department of Surgery, Chonbuk National University Medical School, Jeonju

3College of Nursing, Chonnam National University, Gwangju

4Department of Hematology, Chonnam National University Hwasun Hospital, Hwasun

5Department of Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea

1College of Nursing, Chonbuk National University, Jeonju

2Department of Surgery, Chonbuk National University Medical School, Jeonju

3College of Nursing, Chonnam National University, Gwangju

4Department of Hematology, Chonnam National University Hwasun Hospital, Hwasun

5Department of Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea

Address reprint requests to : Kang, Jeong Hee College of Nursing, Chonbuk National University, 567 Baekje-daero, Deokjin-gu, Jeonju 561-756, Korea Tel: +82-63-270-3125 Fax: +82-63-270-3127 E-mail: jeonghee@jbnu.ac.kr
• Received: July 14, 2014   • Revised: July 18, 2014   • Accepted: October 14, 2014

Copyright © 2014 Korean Society of Nursing Science

This is an Open Access article distributed under the terms of the Creative Commons Attribution NoDerivs License. (http://creativecommons.org/licenses/by-nd/4.0) If the original work is properly cited and retained without any modification or reproduction, it can be used and re-distributed in any format and medium.

  • 256 Views
  • 6 Download
  • 27 Crossref
  • 24 Scopus
prev next
  • Purpose
    This study was performed to assess the reliability and validity of the Korean version of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Chemotherapy-induced peripheral neuropathy 20 items (EORTC QLQ-CIPN20) in patients receiving neurotoxic chemotherapy.
  • Methods
    A convenience sample of 249 Korean cancer patients, previously or currently, being treated with peripheral neurotoxic chemotherapeutic agents were asked to fill in the questionnaire. Collected data were analyzed using SPSS 21.0 and AMOS 21.0. Construct validity, known-group validity, concurrent validity, and internal consistency reliability of the Korean version of the QLQ-CIPN20 were evaluated.
  • Results
    Factor analysis confirmed 3 dimensions of CIPN: sensory, motor, and autonomic. The factor loadings of the 20 items on the 3 subscales ranged from .38 to .85. The 3 subscale-model was validated by confirmatory factor analysis (GFI= .90, AGFI= .86, RMSR= .05, NFI= .87, and CFI= .94), and concurrent validity was demonstrated with the EORTC QLQ-C30. Furthermore, the QLQ-CIPN20 established known-group validity. The Cronbach's alpha coefficients for internal consistency of the subscales ranged from .73 to .89.
  • Conclusion
    The Korean version of the EORTC QLQ-CIPN20 showed satisfactory construct, concurrent, and known-group validity, as well as internal reliability.
Table 1.
General and Clinical Characteristics (N=249)
Characteristics Categories n (%) M±SD
Age (year) <49 50 (20.1) 59.92±11.62
50-59 84 (33.7)
60-69 61 (24.5)
≥70 54 (21.7)
Gender Female 136 (54.6)
Male 113 (45.4)
Occupation Employed 57 (22.9)
Unemployed 192 (77.1)
Education Under or equal to elementary school graduate 62 (24.9)
Middle school graduate 41 (16.4)
High school graduate 101 (40.6)
Over or equal to college graduate 45 (18.1)
Type of cancer Breast cancer 82 (32.9)
Colon & rectal cancer 51 (20.5)
Gastric cancer 24 (9.6)
Esophageal cancer 4 (1.6)
Bile duct cancer 5 (2.8)
Ovarian cancer 4 (1.6)
Lung cancer 3 (1.2)
Malignant lymphoma 31 (12.4)
Multiple myeloma 32 (12.9)
Leukemia 8 (3.2)
Others 5 (1.3)
Time since diagnosis (month) <5 35 (14.0)
5-12 65 (26.1)
13-24 48 (19.3)
25-36 37 (14.9)
37-48 18 (7.2)
≥49 46 (18.5)
Stage (n=178) Stage 2 22 (12.4)
Stage 3 52 (29.2)
Stage 4 104 (58.4)
Current chemotherapy Yes 169 (67.9)
No 80 (32.1)
Duration of CIPN (month) <5 73 (29.3)
5-12 68 (27.3)
13-24 48 (19.3)
≥25 60 (24.1)
ECOG PS 0 71 (28.5)
1 151 (60.6)
2 27 (10.9)

CIPN=Chemotherapy-induced peripheral neuropathy; ECOG PS=Eastern Cooperative Oncology Group performance status.

Table 2.
Construct Validity and Reliability
Constructs Items Factor loading Error estimate CR AVE Inter-subscale correlation Cronbach’s alpha
Sensory Did you have tingling fingers or hands? .62 .46 .90 .50 .42~.53* .89
Did you have tingling toes or feet? .70 .43
Did you have numbness in your fingers or hands? .68 .44
Did you have numbness in your toes or feet? .72 .38
Did you have shooting or burning pain in your fingers or hands? .66 .44
Did you have shooting or burning pain in your toes or feet? .67 .45
Did you have problems standing or walking because of difficulty feeling the ground under your feet? .85 .29
Did you have difficulty distinguishing between hot and cold water? .54 .55
Did you have difficulty hearing? .54 .55
Motor Did you have cramps in your hands? Did you have cramps in your feet? .38 .70 .78 .50 .89 .52 .53~.54* .88
Did you have a problem holding a pen, which made writing difficult? .80 .38
Did you have difficulty manipulating small objects with your fingers (for example, fastening small buttons)? .71 .40
Did you have difficulty opening a jar or bottle because of weakness in your hands? .83 .30
Did you have difficulty walking because your feet dropped downwards? .67 .47
Did you have difficulty climbing stairs or getting up out of a chair because of weakness in your legs? .68 .49
If you drive a car, did you have difficulty using the pedals? .66 .44
Autonomic Were you dizzy when standing up from a sitting or lying position? .83 .30 .74 .60 .42~.54* .73
Did you have blurred vision? .78 .39
If you are a man, did you have difficulty getting or maintaining an erection? .39 .75

*p<.001; CR=Composite reliability; AVE=Average variance extracted.

Table 3.
Model Fit Test
Model Items Absolute fit index
Incremental fit index
χ2 (p) χ2/df GFI AGFI RMSR NFI CFI
Model 1 20 231.89 (<.001) 1.58 .90 .86 .05 .87 .94
Model 2 18 209.66 (<.001) 1.58 .91 .87 .05 .87 .95

GFI=Goodness of fit index; AGFI=Adjusted goodness of fit index; RMSR=Root mean square residual; NFI=Normal fit index; CFI=Comparative fit index.

Table 4.
Correlations between the QLQ-C30 and QLQ-CIPN20 for Concurrent Validity
QLQ-C30 QLQ-CIPN20
Sensory
Motor
Autonomic
r (p) r (p) r (p)
Global health status −.32 (<.001) −.28 (<.001) −.30 (<.001)
Functional −.51 (<.001) −.58 (<.001) −.60 (<.001)
Symptom .49 (<.001) .51 (<.001) .57 (<.001)

QLQ-C30=Cancer Core Quality of Life Questionnaire 30 items; QLQ-CIPN20=Quality of life questionnaire chemotherapy-induced peripheral neuropathy 20 items.

Table 5.
Known-group Validity Tests
ECOG PS QLQ-CIPN20
Sensory
Motor
Autonomic
M±SD F (p) M±SD F (p) M±SD F (p)
0 15.39±16.12 13.28 (<.001) 14.92±16.51 12.62 (<.001) 30.97±19.51 10.34 (<.001)
1 28.73±19.57 26.72±19.48 37.18±20.35
2 39.23±19.85 37.45±17.37 55.00±22.78

ECOG PS=Eastern Cooperative Oncology Group performance status; QLQ-CIPN20=Quality of life questionnaire chemotherapy-induced peripheral neuropathy 20 items.

  • 1. Azhary H, Farooq MU, Bhanushali M, Majid A, Kassab MY. Peripheral neuropathy: Differential diagnosis and management. American Family Physician. 2010;81(7):887–892.PubMed
  • 2. Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20. European Journal of Cancer. 2005;41(8):1135–1139. http://dx.doi.org/10.1016/j.ejca.2005.02.012ArticlePubMed
  • 3. Dunlap B, Paice JA. Chemotherapy-induced peripheral neuropathy: A need for standardization in measurement. The Journal of Supportive Oncology. 2006;4(8):398–399.PubMed
  • 4. Delforge M, Bladé J, Dimopoulos MA, Facon T, Kropff M, Ludwig H, et al. Treatment-related peripheral neuropathy in multiple myeloma: The challenge continues. Lancet Oncology. 2010;11(11):1086–1095. http://dx.doi.org/10.1016/s1470-2045(10)70068-1ArticlePubMed
  • 5. Kautio AL, Haanpää M, Kautiainen H, Kalso E, Saarto T. Burden of chemotherapy-induced neuropathy-a cross-sectional study. Supportive Care in Cancer. 2011;19(12):1991–1996. http://dx.doi.org/10.1007/s00520-010-1043-2ArticlePubMedPDF
  • 6. Kiser DW, Greer TB, Wilmoth MC, Dmochowski J, Naumann RW. Peripheral neuropathy in patients with gynecologic cancer receiving chemotherapy: Patient reports and provider assessments. Oncology Nursing Forum. 2010;37(6):758–764. http://dx.doi.org/10.1188/10.onf.758-764ArticlePubMed
  • 7. Tofthagen C, McAllister RD, McMillan SC. Peripheral neuropathy in patients with colorectal cancer receiving oxaliplatin. Clinical Journal of Oncology Nursing. 2011;15(2):182–188. http://dx.doi.org/10.1188/11.cjon.182-188ArticlePubMed
  • 8. Visovsky C, Collins M, Abbott L, Aschenbrenner J, Hart C. Putting evidence into practice: Evidence-based interventions for chemotherapy-induced peripheral neuropathy. Clinical Journal of Oncology Nursing. 2007;11(6):901–913. http://dx.doi.org/10.1188/07.cjon.901-913ArticlePubMed
  • 9. Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Beren-son J, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. Journal of Clinical Oncology. 2006;24(19):3113–3120. http://dx.doi.org/10.1200/jco.2005.04.7779ArticlePubMed
  • 10. Griffith KA, Merkies IS, Hill EE, Cornblath DR. Measures of chemotherapy-induced peripheral neuropathy: A systematic review of psychometric properties. Journal of the Peripheral Nervous System. 2010;15(4):314–325. http://dx.doi.org/10.1111/j.1529-8027.2010.00292.xArticlePubMed
  • 11. Postma TJ, Heimans JJ. Grading of chemotherapy-induced peripheral neuropathy. Annals of Oncology. 2000;11(5):509–513.ArticlePubMed
  • 12. Wickham R. Chemotherapy-induced peripheral neuropathy: A review and implications for oncology nursing practice. Clinical Journal of Oncology Nursing. 2007;11(3):361–376. http://dx.doi.org/10.1188/07.cjon.361-376ArticlePubMed
  • 13. Cavaletti G, Cornblath DR, Merkies IS, Postma TJ, Rossi E, Frigeni B, et al. The chemotherapy-induced peripheral neuropathy outcome measures standardization study: From consensus to the first validity and reliability findings. Annals of Oncology. 2013;24(2):454–462. http://dx.doi.org/10.1093/annonc/mds329PubMed
  • 14. Barton DL, Wos EJ, Qin R, Mattar BI, Green NB, Lanier KS, et al. A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Supportive Care in Cancer. 2011;19(6):833–841. http://dx.doi.org/10.1007/s00520-010-0911-0ArticlePubMedPDF
  • 15. Kim HY, Kang JH, Song CE, Youn HJ. Chemotherapy-induced peripheral neuropathy and quality of life in breast cancer patients. Asian Oncology Nursing. 2013;13(4):222–230. http://dx.doi.org/10.5388/aon.2013.13.4.222ArticlePDF
  • 16. Mols F, Beijers T, Lemmens V, van den Hurk CJ, Vreugdenhil G, van de Poll-Franse LV. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. Journal of Clinical Oncology. 2013;31(21):2699–2707. http://dx.doi.org/10.1200/jco.2013.49.1514ArticlePubMed
  • 17. Kim JH, Choi KS, Kim TW, Hong YS. Quality of life in colorectal cancer patients with chemotherapy-induced peripheral neuropathy. Journal of Korean Oncology Nursing. 2011;11(3):254–262. http://dx.doi.org/10.5388/jkon.2011.11.3.254ArticlePDF
  • 18. Kwak MK, Kim EJ, Lee ER, Kwon IG, Hwang MS. Characteristics and quality of life in patients with chemotherapy-induced peripheral neuropathy. Journal of Korean Oncology Nursing. 2010;10(2):231–239. http://dx.doi.org/10.5388/jkon.2010.10.2.231ArticlePDF
  • 19. Dewolf L, Koller M, Velikova G, Johnson C, Scott N, Bottomley A. EORTC quality of life group translation procedure. 3rd ed. Brussels, BE: EORTC Quality of Life Group; 2009.
  • 20. Tabachnick BG, Fidell LS. Using multivariate statistics. 3rd ed. New York, NY: Harper Collins Publishers; 1996.
  • 21. Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A. The EORTC QLQ-C30 scoring manual. 3rd ed. Brussels, BE: EORTC Quality of Life Group; 2001.
  • 22. Yun YH, Park YS, Lee ES, Bang SM, Heo DS, Park SY, et al. Validation of the Korean version of the EORTC QLQ-C30. Quality of Life Research. 2004;13(4):863–868.ArticlePubMed
  • 23. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute. 1993;85(5):365–376.ArticlePubMed
  • 24. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the eastern cooperative oncology group. American Journal of Clinical Oncology. 1982;5(6):649–655.ArticlePubMed
  • 25. Kim GS. Analysis structural equation modeling. Seoul: Hannarae Publishing Co.; 2007.
  • 26. Nunnally JC, Bernstein IH. Psychometric theory. 3rd ed. New York, NY: McGraw-Hill; 1994.
  • 27. Kim EJ. Accessing factor structure and construct validity of the successful aging inventory. Journal of Korean Academy of Nursing. 2013;43(4):568–578. http://dx.doi.org/10.4040/jkan.2013.43.4.568ArticlePubMed
  • 28. Park HA. Problems and issues in developing measurement scales in nursing. Journal of Nursing Query. 2005;14(1):46–72.
  • 29. Kim SH, Jo MW, Lee SI. Psychometric properties of the Korean short form-36 health survey version 2 for assessing the general population. Asian Nursing Research. 2013;7(2):61–66.ArticlePubMed
  • 30. Lee EH, Moon S, Cho SY, Oh YT, Chun M, Kim SH, et al. Psychometric evaluation of a need scale for cancer patients undergoing follow-up care. Journal of Korean Academy of Nursing. 2010;40(4):551–560. http://dx.doi.org/10.4040/jkan.2010.40.4.551ArticlePubMed

Figure & Data

REFERENCES

    Citations

    Citations to this article as recorded by  
    • Prevalence and predictive factors of chemotherapy-induced peripheral neuropathy in cancer patients: A cross-sectional single-center study in Pakistan
      Ismail Jadoon, Muhammad Arfat Yameen
      Journal of Oncology Pharmacy Practice.2025;[Epub]     CrossRef
    • The association between the circadian misalignment of serum cortisol acrophase and sleep end time with chemotherapy-induced peripheral neuropathy
      Joon Sung Shin, Sanghyup Jung, Geun Hui Won, Sun Hyung Lee, Jaehyun Kim, Saim Jung, Chan-Woo Yeom, Kwang-Min Lee, Kyung-Lak Son, Jang-il Kim, Sook Young Jeon, Han-Byoel Lee, David Spiegel, Bong-Jin Hahm
      Chronobiology International.2025; 42(2): 259.     CrossRef
    • Late sleep phase with respect to core body temperature rhythm is associated with a higher level of chemotherapy-induced peripheral neuropathy in patients with breast cancer
      Joon Sung Shin, Sanghyup Jung, Geun Hui Won, Sun Hyung Lee, Jaehyun Kim, Saim Jung, Chan-Woo Yeom, Kwang-Min Lee, Kyung-Lak Son, Jang-Il Kim, Sook Young Jeon, Han-Byoel Lee, Bong-Jin Hahm
      Biological Rhythm Research.2024; 55(9-10): 457.     CrossRef
    • Peripheral Neuropathy Instruments for Individuals with Cancer: A COSMIN-Based Systematic Review of Measurement Properties
      Silvia Belloni, Arianna Magon, Chiara Giacon, Francesca Savioni, Gianluca Conte, Rosario Caruso, Cristina Arrigoni
      Current Oncology.2024; 31(12): 7828.     CrossRef
    • Efficacy of electroacupuncture in the treatment of peripheral neuropathy caused by Utidelone: Study protocol for a randomized controlled trial
      Chao Lu, Guangliang Li, Dehou Deng, Rongrong Li, Xiaoyu Li, Xukang Feng, Taoping Wu, Xiying Shao, Weiji Chen
      Frontiers in Neurology.2023;[Epub]     CrossRef
    • Effect of cryotherapy on paclitaxel‐induced peripheral neuropathy of the hand in female breast cancer patients: A prospective self‐controlled study
      Ting‐Ting Yang, Hsiang‐Chu Pai, Chiung‐Yao Chen
      International Journal of Nursing Practice.2023;[Epub]     CrossRef
    • Assessing chemotherapy-induced peripheral neuropathy with patient reported outcome measures: a systematic review of measurement properties and considerations for future use
      Tiffany Li, Susanna B. Park, Eva Battaglini, Madeleine T. King, Matthew C. Kiernan, David Goldstein, Claudia Rutherford
      Quality of Life Research.2022; 31(11): 3091.     CrossRef
    • Psychometric Properties of the Korean Version of the Chemotherapy-Induced Peripheral Neuropathy Assessment Tool
      Mi Sook Jung, Mijung Kim, Kyeongin Cha, Xirong Cui, Ji Wan Lee
      Research and Theory for Nursing Practice.2022; 36(4): 422.     CrossRef
    • Efficacy and safety of intravenous administration of high-dose selenium for preventing chemotherapy-induced peripheral neuropathy in platinum-sensitive recurrent ovarian, fallopian or primary peritoneal cancer: study protocol for a phase III, double-blind
      Soo Jin Park, Ga Won Yim, Haerin Paik, Nara Lee, Seungmee Lee, Maria Lee, Hee Seung Kim
      Journal of Gynecologic Oncology.2021;[Epub]     CrossRef
    • Psychometric evaluation of the Arabic Version the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20)
      Loai Abu Sharour
      Applied Neuropsychology: Adult.2021; 28(5): 614.     CrossRef
    • Chemotherapy-induced Peripheral Neuropathy in Patients with Breast Cancer: Associated Factors and Impact on Health-Related Quality of Life
      Yu Hyeon Choe, Soo Hyun Kim, Hyun Soo Oh, Wha Sook Seo, Sun Hee Lee
      Asian Oncology Nursing.2020; 20(2): 83.     CrossRef
    • Non-randomized preliminary study of an education and elastic-band resistance exercise program on severity of neuropathy, physical function, muscle strength and endurance & quality of life in colorectal cancer patients experiencing oxaliplatin-induced peri
      Shu-Chen Chen, Hsiang-Ping Huang, Wen-Shih Huang, Yung-Chang Lin, Tsui-Ping Chu, Randal D. Beaton, Sui-Whi Jane
      European Journal of Oncology Nursing.2020; 49: 101834.     CrossRef
    • Changes in chemotherapy-induced peripheral neuropathy, disturbance in activities of daily living, and depression following chemotherapy in patients with colorectal cancer: A prospective study
      Pok-Ja Oh, Jung Ran Lee, Sook-Kyoung Kim, Jeong-Hye Kim
      European Journal of Oncology Nursing.2020; 44: 101676.     CrossRef
    • Changes in Chemotherapy-induced Peripheral Neuropathy, Sleep Quality, and Quality of Life following Chemotherapy in Stomach Cancer Patients: a Prospective Study
      Pok Ja Oh, Jin Lee, Jeong Hye Kim
      Asian Oncology Nursing.2020; 20(2): 72.     CrossRef
    • Serum neurofilament light chain levels as a biomarker of neuroaxonal injury and severity of oxaliplatin-induced peripheral neuropathy
      Su-Hyun Kim, Moon Ki Choi, Na Young Park, Jae-Won Hyun, Min Young Lee, Ho Jin Kim, Su Kyung Jung, Yongjun Cha
      Scientific Reports.2020;[Epub]     CrossRef
    • A Randomized, Placebo-Controlled Trial Evaluating Changes in Peripheral Neuropathy and Quality of Life by Using Low-Frequency Electrostimulation on Breast Cancer Patients Treated With Chemotherapy
      Si-Yeon Song, Ji-Hye Park, Jin Sun Lee, Je Ryong Kim, Eun Hee Sohn, Mi Sook Jung, Hwa-Seung Yoo
      Integrative Cancer Therapies.2020;[Epub]     CrossRef
    • Psychometric Testing of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire–Chemotherapy-Induced Peripheral Neuropathy 20-Item Scale Using Pooled Chemotherapy-Induced Peripheral Neuropathy Outcome Measures Standard
      Ellen M. Lavoie Smith, Tanima Banerjee, James J. Yang, Celia M. Bridges, Paola Alberti, Jeff A. Sloan, Charles Loprinzi
      Cancer Nursing.2019; 42(3): 179.     CrossRef
    • Rasch model-based testing of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire–Chemotherapy-Induced Peripheral Neuropathy (QLQ-CIPN20) using Alliance for Clinical Trials in Oncology (Alliance) A151408 stu
      Ellen M. Lavoie Smith, Noah Zanville, Grace Kanzawa-Lee, Clare Donohoe, Celia Bridges, Charles Loprinzi, Jennifer Le-Rademacher, James J. Yang
      Supportive Care in Cancer.2019; 27(7): 2599.     CrossRef
    • A Prospective Study of Chronic Oxaliplatin-Induced Neuropathy in Patients with Colon Cancer: Long-Term Outcomes and Predictors of Severe Oxaliplatin-Induced Neuropathy
      Su-Hyun Kim, Woojun Kim, Ji-Hee Kim, Min Ki Woo, Ji Yeon Baek, Sun Young Kim, Seung Hyun Chung, Ho Jin Kim
      Journal of Clinical Neurology.2018; 14(1): 81.     CrossRef
    • The evaluation of changes in peripheral neuropathy and quality-of-life using low-frequency electrostimulation in patients treated with chemotherapy for breast cancer: a study protocol
      Chang eun Jang, Mi Sook Jung, Eun Hee Sohn, Mijung Kim, Hwa-Seung Yoo, Kyeore Bae, Je Ryong Kim, Jin Sun Lee
      Trials.2018;[Epub]     CrossRef
    • The psychometric properties of the Turkish version of the Chemotherapy-Induced Peripheral Neuropathy Assessment Tool (CIPNAT)
      Sevinç Kutlutürkan, Elif Sözeri Öztürk, Fatma Arıkan, Burcu Bayrak Kahraman, Keziban Özcan, Mürvet Artuk Uçar
      European Journal of Oncology Nursing.2017; 31: 84.     CrossRef
    • Correlation Analysis of Organic Acid Comprehensive Profile Markers with Chemotherapy Induced Peripheral Neuropathy in Cancer Patients
      Ji Hye Park, Simon SangYup Sung, Jin Sun Lee, Hwa Seung Yoo
      Journal of Korean Medicine.2017; 38(1): 72.     CrossRef
    • Oxaliplatin-Induced Peripheral Neuropathy and Quality of Life in Patients with Digestive System Cancer
      Hye Young Kim
      Korean Journal of Adult Nursing.2016; 28(3): 343.     CrossRef
    • Reliability and Validity Analysis of an Instrument for Pattern Identification and Evaluation in Chemotherapy-Induced Peripheral Neuropathy
      Ji-hye Park, In-chul Jung, Seo-hyun Lee, Suk-hoon Lee, Seok-cheol Choi, Hwa-seung Yoo
      The Journal of Internal Korean Medicine.2016; 37(4): 631.     CrossRef
    • Reference data of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-CIPN20 Questionnaire in the general Dutch population
      Floortje Mols, Lonneke V. van de Poll-Franse, Gerard Vreugdenhil, Antoinetta J. Beijers, Jacobien M. Kieffer, Neil K. Aaronson, Olga Husson
      European Journal of Cancer.2016; 69: 28.     CrossRef
    • Psychometric Properties of Turkish Version of the Dutch Objective Burden Inventory
      Canan Demir Barutcu, Hatice Mert, Murat Bektaş
      Asian Nursing Research.2015; 9(3): 207.     CrossRef
    • Relationship between Chemotherapy-induced Peripheral Neuropathy and Quality of Life in Patients with Hematologic Malignancies
      Chi Eun Song, Hye Young Kim, Eun Sook Lee
      Korean Journal of Adult Nursing.2015; 27(3): 358.     CrossRef

    • Cite
      CITE
      export Copy Download
      Close
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

      Format:
      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      Include:
      • Citation for the content below
      Reliability and Validity of the Korean Version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire to Assess Chemotherapy-induced Peripheral Neuropathy
      J Korean Acad Nurs. 2014;44(6):735-742.   Published online December 15, 2014
      Close
    • XML DownloadXML Download
    We recommend
    Reliability and Validity of the Korean Version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire to Assess Chemotherapy-induced Peripheral Neuropathy
    Reliability and Validity of the Korean Version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire to Assess Chemotherapy-induced Peripheral Neuropathy
    Characteristics Categories n (%) M±SD
    Age (year) <49 50 (20.1) 59.92±11.62
    50-59 84 (33.7)
    60-69 61 (24.5)
    ≥70 54 (21.7)
    Gender Female 136 (54.6)
    Male 113 (45.4)
    Occupation Employed 57 (22.9)
    Unemployed 192 (77.1)
    Education Under or equal to elementary school graduate 62 (24.9)
    Middle school graduate 41 (16.4)
    High school graduate 101 (40.6)
    Over or equal to college graduate 45 (18.1)
    Type of cancer Breast cancer 82 (32.9)
    Colon & rectal cancer 51 (20.5)
    Gastric cancer 24 (9.6)
    Esophageal cancer 4 (1.6)
    Bile duct cancer 5 (2.8)
    Ovarian cancer 4 (1.6)
    Lung cancer 3 (1.2)
    Malignant lymphoma 31 (12.4)
    Multiple myeloma 32 (12.9)
    Leukemia 8 (3.2)
    Others 5 (1.3)
    Time since diagnosis (month) <5 35 (14.0)
    5-12 65 (26.1)
    13-24 48 (19.3)
    25-36 37 (14.9)
    37-48 18 (7.2)
    ≥49 46 (18.5)
    Stage (n=178) Stage 2 22 (12.4)
    Stage 3 52 (29.2)
    Stage 4 104 (58.4)
    Current chemotherapy Yes 169 (67.9)
    No 80 (32.1)
    Duration of CIPN (month) <5 73 (29.3)
    5-12 68 (27.3)
    13-24 48 (19.3)
    ≥25 60 (24.1)
    ECOG PS 0 71 (28.5)
    1 151 (60.6)
    2 27 (10.9)
    Constructs Items Factor loading Error estimate CR AVE Inter-subscale correlation Cronbach’s alpha
    Sensory Did you have tingling fingers or hands? .62 .46 .90 .50 .42~.53* .89
    Did you have tingling toes or feet? .70 .43
    Did you have numbness in your fingers or hands? .68 .44
    Did you have numbness in your toes or feet? .72 .38
    Did you have shooting or burning pain in your fingers or hands? .66 .44
    Did you have shooting or burning pain in your toes or feet? .67 .45
    Did you have problems standing or walking because of difficulty feeling the ground under your feet? .85 .29
    Did you have difficulty distinguishing between hot and cold water? .54 .55
    Did you have difficulty hearing? .54 .55
    Motor Did you have cramps in your hands? Did you have cramps in your feet? .38 .70 .78 .50 .89 .52 .53~.54* .88
    Did you have a problem holding a pen, which made writing difficult? .80 .38
    Did you have difficulty manipulating small objects with your fingers (for example, fastening small buttons)? .71 .40
    Did you have difficulty opening a jar or bottle because of weakness in your hands? .83 .30
    Did you have difficulty walking because your feet dropped downwards? .67 .47
    Did you have difficulty climbing stairs or getting up out of a chair because of weakness in your legs? .68 .49
    If you drive a car, did you have difficulty using the pedals? .66 .44
    Autonomic Were you dizzy when standing up from a sitting or lying position? .83 .30 .74 .60 .42~.54* .73
    Did you have blurred vision? .78 .39
    If you are a man, did you have difficulty getting or maintaining an erection? .39 .75
    Model Items Absolute fit index
    Incremental fit index
    χ2 (p) χ2/df GFI AGFI RMSR NFI CFI
    Model 1 20 231.89 (<.001) 1.58 .90 .86 .05 .87 .94
    Model 2 18 209.66 (<.001) 1.58 .91 .87 .05 .87 .95
    QLQ-C30 QLQ-CIPN20
    Sensory
    Motor
    Autonomic
    r (p) r (p) r (p)
    Global health status −.32 (<.001) −.28 (<.001) −.30 (<.001)
    Functional −.51 (<.001) −.58 (<.001) −.60 (<.001)
    Symptom .49 (<.001) .51 (<.001) .57 (<.001)
    ECOG PS QLQ-CIPN20
    Sensory
    Motor
    Autonomic
    M±SD F (p) M±SD F (p) M±SD F (p)
    0 15.39±16.12 13.28 (<.001) 14.92±16.51 12.62 (<.001) 30.97±19.51 10.34 (<.001)
    1 28.73±19.57 26.72±19.48 37.18±20.35
    2 39.23±19.85 37.45±17.37 55.00±22.78
    Table 1. General and Clinical Characteristics (N=249)

    CIPN=Chemotherapy-induced peripheral neuropathy; ECOG PS=Eastern Cooperative Oncology Group performance status.

    Table 2. Construct Validity and Reliability

    p<.001; CR=Composite reliability; AVE=Average variance extracted.

    Table 3. Model Fit Test

    GFI=Goodness of fit index; AGFI=Adjusted goodness of fit index; RMSR=Root mean square residual; NFI=Normal fit index; CFI=Comparative fit index.

    Table 4. Correlations between the QLQ-C30 and QLQ-CIPN20 for Concurrent Validity

    QLQ-C30=Cancer Core Quality of Life Questionnaire 30 items; QLQ-CIPN20=Quality of life questionnaire chemotherapy-induced peripheral neuropathy 20 items.

    Table 5. Known-group Validity Tests

    ECOG PS=Eastern Cooperative Oncology Group performance status; QLQ-CIPN20=Quality of life questionnaire chemotherapy-induced peripheral neuropathy 20 items.


    J Korean Acad Nurs : Journal of Korean Academy of Nursing
    Close layer
    TOP